drugset / Trial / NCT03250052

A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

NCT03250052

Phase 1 Completed 39 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate pharmacokinetic interactions and safety between fimasartan and linagliptin in healthy male volunteers.

Timeline

Start
2017-08-14
Primary completion
2017-10-13
Completion
2017-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimasartan Small molecule 120 mg
Subject Linagliptin Small molecule 20 mg

Indications